Compare BridgeBio Pharma Inc (BBIO) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Occidental Petroleum Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Occidental Petroleum Corporation trades at $58.99 (market cap $55.89B). The key difference: Occidental Petroleum Corporation is far larger — about 3.4× BridgeBio Pharma Inc's market cap, and Occidental Petroleum Corporation pays a 2% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | OXY | |
|---|---|---|
Market Cap | $16.61B | $55.89B |
Sector | Health | Energy |
52-Week High | $90.17 | $66.24 |
52-Week Low | $47.29 | $38.92 |
Enterprise Value | $18.16B | $74.65B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Occidental Petroleum (OXY) trades at $55.91, down 0.23% today, with a bullish technical outlook supported by moving averages and a consensus price target of $69.25. Recent Q2 2026 earnings of $2.40 per share beat expectations, driven by higher oil prices and strong cash flow, while the company focuses on debt reduction and targets over $4 billion in sustainable cash flow by 2030.
OXY presents a buy opportunity with solid profitability and growth prospects, but faces risks from oil price volatility and competitive pressures. Analysts are optimistic, with 50% recommending buy, though investors should monitor execution on cash flow targets and energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
